Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?

被引:433
作者
Pett, M. [1 ]
Coleman, N. [1 ]
机构
[1] Fred Hutchinson MRC Res, Med Res Council Canc Cell Unit, Cambridge CB2 0XZ, England
关键词
cervix; human papillomavirus; carcinogenesis; integration; selection; squamous neoplasia;
D O I
10.1002/path.2192
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
An important occurrence in cervical carcinogenesis is deregulated expression of the high-risk human papillomavirus (HR-HPV) oncogenes E6 and E7. Several risk factors for cervical neoplastic progression are likely to contribute to viral oncogene deregulation, particularly integration of HR-HPV into the host genome. Integration represents a by-product of viral infection that is detected in almost 90% of cervical carcinomas. The mechanism of integration is not fully understood, although there is a clear predilection for chromosomal common fragile sites, most likely due to their accessibility for insertion of foreign DNA. Recent work has suggested that an important intermediate stage in cervical carcinogenesis is characterized by transcriptionally silent HR-HPV integrants, which co-exist with viral episomes in infected cells. As episome-derived E2 protein inhibits integrant transcription, clearance of episomes (eg by host innate immunity) is associated with loss of integrant silencing and integrant selection. The process of integration and subsequent clonal selection of integrants can therefore be considered as two independent and biologically distinct events. Indeed, integrated HPV may be viewed as selectable because it represents a form of the virus that is resistant to host mechanisms of viral clearance, enabling infected cells to maintain viral oncogene expression and avoid cell death. Care should be taken in interpreting studies of HPV integration frequency in clinical samples, as the techniques used have assessed either the presence of integrated viral DNA or evidence of transcriptional activity from integrants, but not both. Copyright (C) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:356 / 367
页数:12
相关论文
共 124 条
[1]
High sensitivity detection of HPV-16 in SiHa and CaSki cells utilizing FISH enhanced by TSA [J].
Adler, K ;
Erickson, T ;
Bobrow, M .
HISTOCHEMISTRY AND CELL BIOLOGY, 1997, 108 (4-5) :321-324
[2]
CCAAT displacement protein binds to and negatively regulates human papillomavirus type 6 E6, E7, and E1 promoters [J].
Ai, WD ;
Toussaint, E ;
Roman, A .
JOURNAL OF VIROLOGY, 1999, 73 (05) :4220-4229
[3]
Alazawi W, 2002, CANCER RES, V62, P6959
[4]
Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer [J].
Arias-Pulido, Hugo ;
Peyton, Cheri L. ;
Joste, Nancy E. ;
Vargas, Hernan ;
Wheeler, Cosette M. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (05) :1755-1762
[5]
Translational approaches to improving cervical screening [J].
Baldwin, P ;
Laskey, R ;
Coleman, N .
NATURE REVIEWS CANCER, 2003, 3 (03) :217-226
[6]
The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α [J].
Barnard, P ;
McMillan, NAJ .
VIROLOGY, 1999, 259 (02) :305-313
[7]
Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA [J].
Bechtold, V ;
Beard, P ;
Raj, K .
JOURNAL OF VIROLOGY, 2003, 77 (03) :2021-2028
[8]
AMPLIFICATION OF HUMAN PAPILLOMAVIRUS GENOMES INVITRO IS DEPENDENT ON EPITHELIAL DIFFERENTIATION [J].
BEDELL, MA ;
HUDSON, JB ;
GOLUB, TR ;
TURYK, ME ;
HOSKEN, M ;
WILBANKS, GD ;
LAIMINS, LA .
JOURNAL OF VIROLOGY, 1991, 65 (05) :2254-2260
[9]
THE HUMAN PAPILLOMAVIRUS TYPE-18 (HPV18) E2 GENE-PRODUCT IS A REPRESSOR OF THE HPV18 REGULATORY REGION IN HUMAN KERATINOCYTES [J].
BERNARD, BA ;
BAILLY, C ;
LENOIR, MC ;
DARMON, M ;
THIERRY, F ;
YANIV, M .
JOURNAL OF VIROLOGY, 1989, 63 (10) :4317-4324
[10]
PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802